Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Samsung Medical Center.
Recruitment status was  Recruiting
Information provided by:
Samsung Medical Center Identifier:
First received: September 13, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted
The purpose of this study is to demonstrate the efficacy and safety of donepezil on the recovery of cognitive function in patients with stroke and to delineate the neurophysiologic mechanisms of the therapeutic effect of donepezil on the recovery of cognitive network using functional neuroimaging technique.

Condition Intervention
Drug: Donepezil

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:


Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Ischemic stroke in the territory of right or left middle cerebral artery
  • Post-onset duration of the recent-onset stroke is over 3 months
  • Cognitive deficit ranged from 10 to 26 by minimal mental status examination (MMSE) score
  • Disturbance in activities of daily living (ADL) ranged 0.5 ~ 2.0 by clinical dementia rating (CDR) scale

Exclusion Criteria:

  • Severe internal carotid artery stenosis on the lesion side
  • Cardiac pacemaker or intracranial metal insertion
  • Post-stroke seizure disorder or any evidence of epileptic spikes on electroencephalography (EEG)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00530478

Contact: Yun-Hee Kim, MD, PHD 82-2-3410-2818

Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Yun-Hee Kim, MD, PHD    82-2-3410-2818   
Sponsors and Collaborators
Samsung Medical Center
Principal Investigator: Suk Hoon Ohn, MD, MS Samsung Medical Center
Principal Investigator: Yun Hee Park, MD Samsung Medical Center
  More Information Identifier: NCT00530478     History of Changes
Other Study ID Numbers: 2006-04-023 
Study First Received: September 13, 2007
Last Updated: September 13, 2007
Health Authority: South Korea: Institutional Review Board
South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Samsung Medical Center:
Cognitive function
Cognitive neural network

Additional relevant MeSH terms:
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents processed this record on October 20, 2016